Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
A clinical study compared the results of SUSTAIN 6 and REWIND studies to the effect of semaglutide and dulaglutide on major adverse cardiovascular events (MACE) such as non-fatal heart attack (myocardial infarction, non-fatal stroke, and death due to heart and blood vessel-related diseases
No heart attacks, strokes, or cardiovascular deaths have been attributed to retatrutide in published trial data
Exclusion criteria observed in Phase 2 trials included individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, given the class-level concern with GLP-1 receptor agonists and C-cell tumours in rodent models [8]
The brand uses clinically proven treatments like Semaglutide and other GLP-1 drugs, showing its commitment to evidence-based methods for improving metabolic health and significant weight loss
US$ 22.48
US$ 21.53
US$ 28.51
US$ 27.94
US$ 24.56
&srotate=0)
US$ 27.93
US$ 24.20
US$ 24.15
US$ 27.37
